Abdera Therapeutics is a precision oncology company focused on developing next-generation targeted radiation therapies. Utilizing their proprietary ROVEr™ platform, they aim to deliver radioisotopes that selectively destroy tumor cells while sparing healthy cells. The company is building a pipeline of innovative radiotherapeutics targeting various solid tumors, with plans to initiate Phase 1 clinical trials for small cell lung cancer and large cell neuroendocrine carcinoma. Abdera's unique approach and advanced technology position it as a leader in the rapidly evolving field of radiotherapeutics, addressing significant unmet needs in cancer treatment.
Ability Biologics is a leading biotherapeutic targeting company focused on developing innovative, immune-modulating biotherapeutics to address unmet medical needs in cancer and autoimmune diseases. Utilizing their proprietary Abi Leap™ discovery engine, they produce fully human, Ig G-based multispecific antibodies with exceptional selectivity and affinity. Their technology leverages artificial intelligence and a vast database of antigen-antibody interactions to create highly specific therapeutics. The company is dedicated to advancing preclinical antibody candidates and aims to conduct human proof of concept clinical trials, positioning itself as a key player in the biotherapeutics market.
Deep Genomics is an AI-driven genetic medicine company that focuses on programming RNA therapies for any gene and genetic condition. Their proprietary AI platform, Big RNA, enables the discovery of novel therapeutic candidates by untangling the complexities of RNA biology. With a strong interdisciplinary team of over 100 experts, they have made significant advancements in RNA therapeutic development, including the release of the first Foundation Model for RNA Biology. The company is positioned at the forefront of drug development, leveraging AI to address complex genetic diseases and has received recognition as a leading biotechnology company.
Nomic is a bioengineering company revolutionizing protein profiling with its n ELISA platform, enabling high-throughput and flexible multiplexing for comprehensive immune secretome analysis. Their innovative technology allows for the profiling of over 200 cytokines, achieving a throughput of 10,000+ samples per week, making it the fastest and most seamless protein profiling service available. Nomic's differentiation lies in its ability to provide true multiplexing without cross-reactivity issues, offering a cost-effective solution that meets the growing demand in the life sciences sector. With significant traction and partnerships, Nomic is positioned as a leader in the proteomics market, facilitating advancements in drug discovery and immunotherapy research.
Prilenia is a clinical-stage biotech company founded in 2018, dedicated to developing novel therapeutics for neurodegenerative diseases such as Huntington's disease and amyotrophic lateral sclerosis (ALS). The company focuses on its lead product, Pridopidine, an oral sigma-1 receptor agonist currently in late-stage clinical development, which has an established safety profile. With a team of experienced scientists and drug developers, Prilenia aims to provide hope to patients and families affected by these conditions. The company operates globally with offices in the Netherlands, Israel, and the United States, and is backed by reputable investors, indicating strong market position and traction in the biotech sector.
Repare Therapeutics is a leading clinical-stage precision oncology company focused on synthetic lethality. Utilizing their proprietary SNIPRx® platform, they systematically discover and develop targeted cancer therapies that address genomic instability, particularly in DNA damage repair. Founded in 2016 by leading academics, the company aims to be a leader in biopharmaceuticals by developing small molecule therapies based on synthetic lethality, identifying novel targets, designing selective inhibitors, and expanding treatment options for patients with high unmet medical needs.